NasdaqGS:CMPSBiotechs
Assessing COMPASS Pathways (CMPS) Valuation After Positive Phase 3 COMP360 Trial Milestone
COMPASS Pathways (CMPS) is in focus after reporting that its pivotal Phase 3 COMP005 trial of COMP360 for treatment resistant depression met its primary endpoint, with statistically significant efficacy and a safety profile consistent with earlier studies.
See our latest analysis for COMPASS Pathways.
The Phase 3 readout lands after a series of governance and capital markets updates, including new director appointments, fresh equity incentives for board members and a recent conference...